A Pilot Study of antifungal Prophylaxis with Itraconazole (ITRA) in Allogeneic Hematopoietic Transplant (Allo-HSCT) Recipients after Neutrophil Recovery.

B.H. SEGAL, A. PROEFROCK, D. BALL, C. HSIAO, P. PAPLHAM, G.G. LEITZ, J.M. BULLOCK, P.F. SMITH, A.R. ALAM, P.L. MCCARTHY

Author address: 

Roswell Park Cancer Institute, Buffalo, NY, Ortho Biotech, Inc., Bridgewater, NJ

Abstract: 

Background: Invasive fungal infections (IFI) are a major cause of mortality in Allo-HSCT recipients. Most cases occur after neutrophil recovery during potent immunosuppressive therapy for graft-versus-host disease (GVHD). More effective prophylaxis aimed at high-risk Allo-HSCT recipients is needed. Methods: We evaluated long-term ITRA prophylaxis in 12 Allo-HSCT recipients. Patients received intravenous (IV) ITRA loading for 2 days followed by oral ITRA solution after neutrophil recovery from the conditioning regimen. ITRA was administered on-study until a minimum of 120 days and a maximum of 1 year after transplant, depending on corticosteroid (CS) dosing. ITRA was continued until the CS dose was
2003

abstract No: 

M-974

Full conference title: 

43rd Interscience Conference on Antimicrobial Agents
    • ICAAC 43rd